Antibodies raised against the N-terminal sequence of delta opioid receptors blocked delta-mediated supraspinal antinociception in mice.
A polyclonal antiserum directed against the first 16 amino acids of the N-terminal sequence of the murine delta opioid receptor was raised in rabbits. The intracerebroventricular (i.c.v.) injection to mice of the anti delta receptor IgGs impaired the antinociception produced by DPDPE, [D-Ala2]-Deltorphin II, DADLE and beta-endorphin-(1-31) when studied 24 h later in the tail-flick test. Antinociception produced by morphine and DAMGO was fully expressed in mice undergoing this treatment. The selective delta antagonist ICI 174864 (0.8 nmols/mouse, i.c.v.) significantly reduced the antinociceptive activity of opioids to the extent observed after giving the antibodies. ICI 174864 did not decrease further the antinociception that remained after the anti delta receptor serum. The specific binding displayed by 3 nM [3H]-DPDPE was reduced in membranes pre-incubated with the antiserum, whereas no change could be detected for 0.6 nM [3H]-DAMGO labelling mu receptors. This experimental approach revealed the delta component of opioid-evoked supraspinal antinociception in mice.
Garzón
J
J
Instituto Cajal, C.S.I.C., Madrid, Spain.
Castro
M A
MA
Juarros
J L
JL
Sánchez-Blázquez
P
P
D000595:Amino Acid Sequence; D000704:Analysis of Variance; D000818:Animals; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D020881:Enkephalin, D-Penicillamine (2,5)-; D004743:Enkephalin, Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D016308:Enkephalin, Leucine-2-Alanine / Q000037:antagonists & inhibitors; D004745:Enkephalins / Q000037:antagonists & inhibitors / Q000494:pharmacology; D019204:GTP-Binding Proteins / Q000378:metabolism; D007074:Immunoglobulin G / Q000276:immunology; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008969:Molecular Sequence Data; D009020:Morphine / Q000037:antagonists & inhibitors; D009292:Narcotic Antagonists / Q000494:pharmacology; D009842:Oligopeptides / Q000037:antagonists & inhibitors; D010146:Pain / Q000503:physiopathology*; D010147:Pain Measurement; D011485:Protein Binding / Q000187:drug effects; D011930:Reaction Time; D017465:Receptors, Opioid, delta / Q000032:analysis* / Q000037:antagonists & inhibitors* / Q000187:drug effects; D001615:beta-Endorphin / Q000037:antagonists & inhibitors
D004745:Enkephalins; D007074:Immunoglobulin G; D009292:Narcotic Antagonists; D009842:Oligopeptides; D017465:Receptors, Opioid, delta; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; C060209:deltorphin II, Ala(2)-; D004743:Enkephalin, Leucine; D001615:beta-Endorphin; D016308:Enkephalin, Leucine-2-Alanine; D009020:Morphine; D020881:Enkephalin, D-Penicillamine (2,5)-; C040643:N,N-diallyl-tyrosyl-alpha-aminoisobutyric acid-phenylalanyl-leucine; D019204:GTP-Binding Proteins